Introduction
Angiogenesis plays an important role in tumor growth (Thairu et al., 2011) because blood vessels generated via this pathophysiological process supply oxygen and nutrients to cancer cells and subsequently remove carbon dioxide and metabolites, both of which are indispensable to the proliferation and survival of cells (McMahon, 2000; Bhat and Singh, 2008; Claesson-Welsh, 2012) . Considerable evidence shows that appropriate suppression of tumor angiogenesis can attenuate tumor growth (Bhat and Singh, 2008; Claesson-Welsh, 2012) . Vascular endothelial growth factor (VEGF)-A is a key regulator of angiogenesis.
Angiogenesis-related VEGF signaling is mediated primarily by VEGF receptor 2 (VEGFR2/KDR) activation (Takahashi, 2011; Nagy et al., 2007; Shibuya, 2014) , which activates various cell-signaling molecules, such as phosphoinositide 3-kinase/Akt, Cdc42/p38 mitogen-activated protein (MAP) kinase, focal adhesion kinase (FAK), Src family kinase, phospholipase C (PLC)/protein kinase C (PKC), and mitogen extracellular kinase (MEK)/extracellular signal-related kinase (ERK) (Zachary and Gliki, 2001 ).
L-Carbocisteine (S-carboxymethylcysteine) is used widely as an expectorant (Rhinathiol®, Mucodyne®) because it normalizes sialic acid and fucose contents in mucins through the regulation of glycosyltransferase activity, and its use is not associated with serious side effects. L-Carbocisteine removes phlegm and indications for its use include inflammation of the upper respiratory tract, acute bronchitis, bronchial asthma, chronic bronchitis, This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on June 30, 2015 as DOI: 10.1124 at ASPET Journals on April 19, 2017 jpet.aspetjournals.org Downloaded from J  P  E  T  #  2  2  4  8  1  6 5 bronchiectasis, pulmonary tuberculosis, and chronic sinusitis (Hooper and Calvert, 2008) . In recent years, novel biological activities of L-carbocisteine have been reported in the context of inhibition of inflammation associated with influenza virus infection and chronic obstructive pulmonary disease (COPD) (Yamaya et al., 2010; Asada et al., 2012; Yasuda et al., 2006; Zheng at al., 2008) . Another report showed that L-carbocisteine possessed free radical-scavenging properties in vitro (Nogawa, 2009) . Various inflammatory cells, including neutrophils, mast cells, natural killer cells, macrophages, and dendritic cells, are involved in induction and promotion of angiogenesis (Noonan et al., 2008; Kim et al., 2013) . Moreover, generation of reactive oxygen species (ROS) is a primary function of activated inflammatory cells, which serve as important stimuli for angiogenic signaling (Kim et al., 2013; Reuter et al., 2010; Grote et al., 2011) . However, the effects of L-carbocisteine on angiogenesis have not been reported.
We hypothesized that L-carbocisteine produces anti-angiogenic activity, and tested this hypothesis in vitro and in vivo, because an understanding of the molecular mechanisms and targets of established drugs is essential for safe drug use and the development of novel indications.
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Materials and Methods

Antibodies and reagents
L-Carbocisteine was a gift from Kyorin Pharmaceutical Co. (Tokyo, Japan).
L-2-Aminoadipic acid was obtained from TCI (Tokyo, Japan). Human recombinant VEGF 165 and epidermal growth factor (EGF) were purchased from PeproTech (Rocky Hill, NJ, USA).
Anti-phospho-Akt ( 
Cell culture
Animals
Specific pathogen-free inbred C57BL6/JJms mice (weighing 19-21 g) and BALB/cCr mice (weighing 20-22 g) for use in this study were obtained from Japan SLC, Inc. (Shizuoka, Japan) and housed in a laminar airflow room with a 12-h light-dark cycle under specific pathogen-free conditions. All animals were allowed to acclimatize to their new environment for 1 week before experimentation. The animal experiments were performed according to the guidelines of the Kyushu University of Health and Welfare (Nobeoka, Japan), which complied with the "Law Concerning the Protection and Control of Animals" and "Standards relating to the care and management, etc. of experimental animals'' (Office of the Prime
Minister of Japan; http://law.e-gov.go.jp).
In vivo angiogenesis assay
This article has not been copyedited and formatted. The final version may differ from this version. The in vivo anti-angiogenic activity of L-carbocisteine was assessed with a Matrigel plug assay as described elsewhere (Suehiro et al., 2010) . Matrigel was mixed with vehicle or 30 ng/mL of VEGF and injected subcutaneously in a 500-μL bolus into the flank of a 6-week-old male C57BL/6JJms mouse. Injected mice were treated twice daily with or without L-carbocisteine (2.5 mg/kg administered intraperitoneally). On day 14, mice were injected with 50 μ L of 1% Evans blue solution via the orbital vein. After 1 h, mice were perfused with phosphate-buffered saline (PBS) containing 2 mM EDTA by intravenous injection into the left ventricle of the heart. Matrigel pellets were harvested and incubated with formamide for 2 days to elute Evans blue dye. Neovascular densities were determined by measuring the absorbance of pellets at 620 nm.
Cell viability assay
Cell viability was assessed with the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan), 
Migration assay
HUVECs were seeded on 35-mm plates and allowed to form confluent monolayers. Cells
This article has not been copyedited and formatted. The final version may differ from this version. were starved overnight in VEGF and basic fibroblast growth factor (bFGF)-free EGM-2 medium and pretreated with L-carbocisteine for 30 min. Monolayers were subjected to scratch wounding with a sterile 200-μL pipette tip in the presence or absence of VEGF. Cells were incubated for 18 h before observation using a phase-contrast microscope. Four randomly selected fields were photographed and the number of migrated cells was determined manually.
Assay to measure formation of HUVEC tubular networks
HUVEC tubular networks were formed according to a published method (Uchiyama, 2010) .
Two volumes of Cellmatrix Type I-A were mixed with 5 volumes of 0.1% acetic acid, 2 volumes of 5× NaHCO 3 -free DMEM, and 1 volume of reconstitution buffer, and the resulting solution was placed on ice. This mixture (800 μ L) was added to each well of a 12-well plate, which was incubated at 37 °C for 30 min to allow formation of a bottom gel layer. HUVECs were seeded into each gel-containing well at a density of 1.0 × 10 4 cells/well and incubated for 6 h to allow adherence to the collagen gel. The cultured medium was removed gently, and 500 μ L of the collagen mixture was added atop the bottom layer, followed by solidification at 37 °C for 30 min (top layer). phase-contrast microscopy: 4 randomly selected fields were photographed and total tubule lengths were measured.
Immunoblotting
Preparation of cell lysates and immunoblotting were conducted as described previously (Takeuchi et al., 2009 
Colon-26 tumor-bearing mice
A Colon-26 tumor-bearing mouse model assay was set up as described previously, with some modifications (Acharyya et al., 2004 
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Results
L-Carbocisteine inhibits VEGF-induced proliferation, migration, and formation of tubular structures of endothelial cells
To assess 
L-Carbocisteine inhibits VEGF-induced angiogenesis in vivo
To ascertain the effects of L-carbocisteine on angiogenesis in vivo, we conducted a Matrigel plug assay. VEGF-loaded Matrigel (30 ng/mL) was stained positively with Evans blue, suggesting that new blood vessels formed within the Matrigel via VEGF-induced angiogenesis ( Fig suppressed by L-carbocisteine. In contrast, pretreatment with L-carbocisteine significantly suppressed the phosphorylation of PLCγ and PKCμ (Figs. 5A-C). In addition, L-carbocisteine inhibited MEK1/2 phosphorylation after VEGF treatment (Fig. 5D ).
L-Carbocisteine attenuates the association of PLCγ with VEGFR2
To determine whether L-carbocisteine suppresses the formation of the PLCγ/VEGFR2 complex, cell lysates were immunoprecipitated with antibodies against VEGFR2 or PLCγ and immunoblotted with reciprocal antibodies. VEGF stimulated complex formation in
HUVECs, whereas pretreatment with L-carbocisteine prevented complex formation (Fig. 6 ).
L-Carbocisteine suppressed signals for angiogenesis by inhibiting VEGF-induced formation of the PLCγ/VEGFR2 complex ( Fig. 7 ).
L-Carbocisteine suppresses the tumor growth and angiogenesis
To determine the effects of L-carbocisteine on tumor growth and angiogenesis in vivo, we evaluated the effect of L-carbocisteine in Colon-26 tumor-bearing mice. For this purpose, we injected Colon-26 tumor cells into male BALB/c mice, following which they were orally administered various concentration of L-carbocisteine (experimental group) or vehicle (control group) daily for 26 days ( To determine whether L-carbocisteine directly induces apoptosis in tumor cells, we tested the effect of L-carbocisteine on Colon-26 cell viability. We found that treatment with a high concentration (approximately 500 µM) of L-carbocisteine had no effect on Colon-26 cell proliferation (Fig. S2A ). Subsequently, we used western blot analysis to examine the effect of L-carbocisteine on growth factor-induced phosphorylation of ERK1/2 in tumor cells, and found that L-carbocisteine did not suppress EGF-induced activation of ERK1/2 in Colon-26 cells (Fig. S2B ).
L-2-Aminoadipic acid inhibits VEGF-induced proliferation and activation of ERK1/2 in endothelial cells
L-2-Aminoadipic acid is a substitution product of L-carbocisteine (sulfur to carbon). To confirm whether sulfur is important for the anti-angiogenic effect of L-carbocisteine, we
This article has not been copyedited and formatted. The final version may differ from this version. This is the first report to demonstrate comprehensively that L-carbocisteine inhibits angiogenesis and tumor growth. Unlike conventional anti-cancer agents, the uses of which are complicated by various side effects and/or severe cytotoxicity, L-carbocisteine produces exceptional anti-angiogenic activity without cytotoxicity or side effects.
Angiogenesis is a complex, multistep process that involves the proliferation, migration, and tubular-network formation of endothelial cells (Patan, 2004) , and inhibition of any step of this process has been shown to prevent formation of new blood vessels (Tournaire et al., 2004) . In this study, we showed that L-carbocisteine significantly inhibits endothelial cell proliferation in a concentration-dependent manner (Fig. 1A) . tyrosine kinases, VEGFR2 forms a complex with and subsequently phosphorylates PLCγ, which is critical for ERK activation (Takahashi et al., 2001; Takahashi and Shibuya 1997; Wu, 2000) . In contrast, Ras is weakly activated by VEGF (Takahashi et al., 1999) . VEGF stimulates activation of PKCµ (PKD) via the VEGFR2/PLCγ/PKC pathway. PKCµ in endothelial cells is rapidly phosphorylated at Ser744/Ser748 in response to VEGF, and PKCµ is involved in VEGF-induced ERK signaling and endothelial cell proliferation (Wong et al., 2005) . In the present study, L-carbocisteine had no effect on VEGFR2 phosphorylation. 
Similar to L-carbocisteine, N-acetylcysteine (NAC) is a cysteine-derivative mucolytic drug
This article has not been copyedited and formatted. The final version may differ from this version. (Albini et al., 1995) . NAC has also been shown to exert direct cytoprotective and anti-genotoxic effects on endothelial cells (Aluigi et al., 2000) .
Given the possible association between NAC treatment and reduced tumor-dependent angiogenesis, a reported and potentially important aspect of the effectiveness of NAC is its ability to limit VEGF expression (Albini et al., 2001; Agarwal et al., 2004) , and this effect may be related to its suppression of ROS and hypoxia-induced transcription via hypoxia inducible factor-1 (Agarwal et al., 2004; Albini et al., 1995; Sceneay et al., 2013) . Therefore, the anti-angiogenic effects of NAC are due to its anti-oxidant activity and are distinct from the anti-angiogenic effects of L-carbocisteine reported in the present study. Because sulfur compounds have strong anti-ROS activity, we considered whether the inhibitory effect of L-carbocisteine on VEGF-induced ERK activation was based on anti-ROS activity. We showed that L-2-aminoadipic acid inhibited proliferation and activation of ERK1/2 in VEGF-stimulated endothelial cells (Fig. 9) , indicating that the anti-angiogenic effect of L-carbocisteine is not conferred by its constituent sulfur. We believe that steric effects associated with L-carbocisteine and L-2-aminoadipic acid are important to their This article has not been copyedited and formatted. The final version may differ from this version. , 2011) . In the present study, we found that L-carbocisteine suppressed VEGF-induced ERK1/2 activation but had no effect on activation of Akt, JNK, or p38 MAP kinase (Figs. 3A-D) . Furthermore, the usual oral dose of L-carbocisteine prescribed to adults is 500 mg of L-carbocisteine (3 times daily). In our study, L-carbocisteine inhibited angiogenesis, but did so at a dose about 10 times greater than the normally prescribed dose. One of the reasons why a higher concentration of L-carbocisteine was required is its short biological half-life (t 1/2 ) (about 2 h; from a medical package insert of Mucodyne periods. The cells were harvested and equal aliquots of protein extracts were immunoprecipitated with antibodies against VEGFR2 or PLCγ. Immunoprecipitates were subjected to SDS-PAGE and blotted with antibodies against PLCγ or VEGFR2 as indicated.
Total cell extracts were prepared and subjected to SDS-PAGE for detection of VEGFR2 and
PLCγ. The blot was reprobed with beta-actin antibodies as a loading control. Data are presented as mean ± S.E.M. from 3 independent experiments. *, P < 0.05. 
